Corrected: Westlake targets $450M for Seidenberg’s next life sciences fund

Life sci­ences VC firm West­lake Vil­lage BioPart­ners is ready to re­stock its cap­i­tal re­serves short­ly af­ter its suc­cess with bring­ing port­fo­lio com­pa­ny Ace­lyrin to one of the biggest IPOs in re­cent biotech mem­o­ry.

The Los An­ge­les ven­ture firm — led by well-known ex-Klein­er Perkins in­vestor Beth Sei­den­berg — eyes a $450 mil­lion fund, per a Thurs­day SEC fil­ing. West­lake’s oth­er found­ing man­ag­ing di­rec­tor, for­mer Am­gen R&D ex­ec­u­tive Sean Harp­er, is not list­ed on the SEC fil­ing as a par­tic­i­pant in the fund.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN